Analysts expect that Opiant Pharmaceuticals Inc (NASDAQ:OPNT) will announce earnings of ($0.82) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Opiant Pharmaceuticals’ earnings. Opiant Pharmaceuticals posted earnings per share of $0.15 during the same quarter last year, which would indicate a negative year over year growth rate of 646.7%. The firm is scheduled to report its next earnings results on Wednesday, June 14th.
According to Zacks, analysts expect that Opiant Pharmaceuticals will report full-year earnings of $2.94 per share for the current financial year. For the next fiscal year, analysts expect that the business will post earnings of ($4.83) per share. Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Opiant Pharmaceuticals.
ILLEGAL ACTIVITY WARNING: This piece was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://transcriptdaily.com/2017/06/17/opiant-pharmaceuticals-inc-opnt-expected-to-post-earnings-of-0-82-per-share-updated.html.
Opiant Pharmaceuticals (NASDAQ:OPNT) traded down 3.61% during mid-day trading on Wednesday, reaching $6.35. 980 shares of the company’s stock traded hands. The stock has a market cap of $12.93 million and a P/E ratio of 1.41. Opiant Pharmaceuticals has a 12 month low of $5.01 and a 12 month high of $9.06. The company has a 50 day moving average price of $6.59 and a 200-day moving average price of $7.12.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opiant Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.